Introduction
antioxidants, or combinations of a few antioxidants. For example the intervention trials with b-carotene convincingIt is widely agreed that increased consumption of fruits, ly demolished the concept that this carotenoid is an grains and vegetables, decreased intake of saturated fats, a important anti-cancer agent in humans, at least in smokers moderate degree of exercise and perhaps judicious con- [30] . Hence high plasma levels of b-carotene are negasumption of red wine or other alcoholic beverages (or even tively associated with cancer incidence because both are a tea) would improve the cardiovascular health of the consequence of eating a good diet; b-carotene is not the populations in most developed and 'near-developed' counprotective agent in that diet [30] . Indeed, the 'antioxidant tries [1] [2] [3] [4] [5] [6] [7] [8] . Fruits, grains, teas, vegetables and red wines hypothesis' might have predicted this: by comparison with are rich in antioxidants (ascorbate, tocopherols, tocotflavonoids, tocopherols and ascorbate, b-carotene is a poor rienols, flavonoids, other phenols and carotenoids are antioxidant even in vitro and probably unlikely to be any among the antioxidants found in various plants consumed better in vivo [31] . This is further illustrated by the by humans; reviewed in [9] ), and so it is widely thought observation that increased vegetable and fruit consumpthat antioxidants make an important contribution to this tion, and (under some circumstances) physical exercise, cardiovascular protective effect [9] [10] [11] [12] [13] [14] . This assumption is can decrease levels of oxidative DNA damage (a putative logical, because there is good evidence that oxidative risk factor for cancer development) in humans and other damage contributes to the pathology of atherosclerosis and animals, and high-fat diets can increase these levels, but vascular dysfunction generally, and that free radicals are b-carotene supplements have little or no effect on levels of involved in myocardial ischemia-reperfusion injury [9,15- oxidative DNA damage in the human body [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] . 20]. However, intervention trials with vitamin E that assess Is the situation any different for cardiovascular disease? clinical end-points are giving a confused picture [21] [22] [23] .
There is little evidence that b-carotene has any direct Indeed, foods and beverages derived from plants are effect on incidence of cardiovascular disease or diabetes chemically complex, and cardiovascular protective effects [43] [44] [45] [46] . Data on the relation of vitamin C intake to could also arise from many other components or mixtures cardiovascular disease are conflicting, but no consensus of components present, including fibre, immunostimulatory has emerged for a cardiovascular protective effect agents, monounsaturated fatty acids, agents that modulate [43, 44, 47] , although the suggested association of low cholesterol synthesis, B-vitamins, folic acid, agents moduascorbate intake with hypertension is intriguing [48, 49] . lating nitric oxide production, and even the humble ethanol Improved vascular function in some subjects has been molecule itself [2, 3, 5, 6, 14, [24] [25] [26] [27] [28] [29] .
reported after consumption of gram quantities of ascorbate One obvious way to assess the contribution of anti- [50] [51] [52] , but it is uncertain as to whether antioxidant or oxidants to the cardiovascular protective effects of the other properties of ascorbate are responsible [53] . In above diets is to conduct intervention trials with single relation to cardiovascular disease prevention, vitamin E is perhaps the most controversial antioxidant, with results of lated to their antioxidant activity. Examples include putasupplementation trials ranging from dramatic protective tive effects on blood pressure, cell proliferation, monocyte actions to absence of effect [21] [22] [23] 46, 54, 55] . function, vascular responsiveness and blood coagulation [48] [49] [50] [51] [52] [60] [61] [62] [63] [64] . The criteria that should be met by the 'ideal' assay of result is predictable from our initial hypothesis, i.e. carlipid peroxidation are summarised in Table 1 . No existing diovascular disease incidence will not drop because we assay meets all these criteria, but some are better than have not inhibited the oxidative damage that contributes to others. First, lipid peroxidation should not be measured in it [57] . For example, a recent comprehensive review [58] human tissues or body fluids by simple diene conjugation concluded that there was little convincing evidence that methods or determinations of thiobarbituric acid-reactive vitamin C supplements had lowered levels of oxidative material (TBARS), except where they have been previousdamage in human intervention studies. One reason may be ly calibrated against more sophisticated assays. The simple that many such studies have been carried out on subjects TBA test and diene conjugation methods are flawed who already had sufficient tissue and body fluid levels of (reviewed in [9, 68] ). vitamin C to achieve the maximal antioxidant effect. There
The peroxidation that contributes to atherosclerosis is is evidence from studies of oxidative DNA damage that thought to occur within blood vessel walls and not (or at intakes of ascorbate of 100-200 mg per day maximize its least not to a large extent) in LDL circulating in the blood protective effects, and higher intakes may even increase [15, 16] . Just as LDL can enter vessel walls, minimally oxidative DNA damage (reviewed in [59] ). If the putative modified LDL (i.e. LDL that has undergone some oxidaprotective effect of ascorbate against cancer development tion, but insufficient for recognition by scavenger reis due to its antioxidant properties in protecting DNA ceptors) may escape back into the circulation. Therefore, against oxidative damage, supplementation carried out on one potentially useful biomarker perhaps indicative of populations who already had intakes of 100-200 mg per peroxidation in blood vessels may be the susceptibility of day would be expected to reveal no effect. As I have circulating LDL to peroxidation. Indeed, this assay is stressed recently [57] , it is pointless to do large intervenwidely used to show that antioxidants that inhibit lipid tion trials with antioxidants in humans without preceding peroxidation in vitro might exert effects in vivo [69, 70] . and accompanying studies to show that the antioxidant at
The dietary manipulation [66, 67] or antioxidant supplethe dose to be given is capable of decreasing oxidative ment is administered to the subject and LDL is subsequentdamage significantly in the population in question. Unless ly isolated and subjected to prooxidant challenge. This this is shown, it will be impossible to interpret the trial technique has been used by the group of Esterbauer and results in relation to the initial hypothesis.
others [69, 70] to investigate the optimal intake of vitamin A parallel question is whether vitamins E, C and E to make LDL most resistant to peroxidation. That intake carotenoids exert cardiovascular protective effects unreturns out to be higher (.150 IU of RRR-a-tocopherol) (6) It should be able to assess both steady-state levels of peroxidation products (i.e. the balance between rates of peroxidation and rates of metabolism / clearance of peroxidation products) and total rates of ongoing lipid peroxidation. (7) The parameter measured should be stable on storage (essential for human epidemiological studies) and should not be formed artifactually in stored samples.
a Adapted from [134] . b If plasma peroxides are cytotoxic and contribute to atherosclerosis, it does not perhaps matter in terms of cardiovascular damage if they originate from diet or endogenously. However, when assessing effects of dietary changes on lipid peroxidation in vivo spurious answers can be obtained if the 'peroxide load' of the diet is changed by the intervention, and it is better to use an assay that is not confounded by this. than can be achieved by relying on foods as a source of A related approach is to measure the levels of circulatvitamin E. This is consistent with the epidemiological data; ing antibodies against LDL, which is presumably related to although there is considerable disagreement, the results of the extent of LDL oxidation in vivo [87, 88] . It should be intervention trials suggest that the intakes of vitamin E that noted, however, that the precise relationship of LDL exert cardiovascular benefit in some studies are higher than oxidation in the vessel wall to LDL oxidation in plasma can be obtained from diet alone [22, 55, 71] . The ex vivo remains to be clearly elucidated. LDL peroxidation method has also been used to examine the effects of consumption of wines and teas on LDL 4.1. Direct assays of lipid peroxidation peroxidisability in humans: several papers suggest that tea has no effect [71] [72] [73] [74] usually achieved by adding Cu ions. There is evidence (Table 2) . Similar values are often given by TBA tests that copper plays a role in LDL oxidation in vivo [80, 81] , linked to HPLC to remove interfering chromogens [9, 68] . but peroxynitrite, reactive chlorine species, haem proteins, By contrast, methods based on direct HPLC analysis of hydroxyl radicals, and lipoxygenases could also be inplasma peroxides produce lower values, usually ,40 nM volved [81] [82] [83] [84] [85] [86] and the predominant oxidizing species for the total of phospholipid and cholesterol ester hymay differ from lesion to lesion or even in different droperoxides assayed by HPLC with coulometric or regions of the same lesion. It is sensible to check several luminescence detection [89, 90] . Is it that the simpler different methods (including incubating the LDL with methods (Table 2) are non-specific, measuring other endothelial and other cell types found in the vessel wall) of oxidizing species (e.g. protein peroxides [82] ), or is it that oxidising LDL in ex vivo studies before forming concluthe more complex methods degrade peroxides or otherwise sions about the efficacy of administered antioxidants. For fail to measure some of them during analysis [91] ? 21 example, an antioxidant that inhibits Cu -dependent LDL The GC-MS-based analysis of specific peroxides after 21 oxidation ex vivo by chelating Cu may not be effective reduction to alcohols is a chemically robust technology in lesions in which the predominant LDL oxidation is (Table 1) and gives information about the peroxidation of achieved by other mechanisms. Another problem is that individual fatty acid residues [92, 93] . For example concertain amphipathic antioxidants may protect LDL in the centrations of C18 hydroxyacid in plasma of healthy men plasma environment but wash out during the prolonged and women were approximately 1 mM, whereas C20 procedures often used to purify LDL, so that they could hydroxyacid concentrations were 100-150 nM [92, 93] . exert protection in vivo but appear to exert no effect in ex However, these methods will measure hydroxyacids (lipid vivo studies. This could conceivably happen with many alcohols) originally present in the biological material, in plant phenolics, which have some degree of solubility in addition to those generated from the peroxides present by aqueous media. the reduction step prior to analysis. Other chemically robust methods include analysis of end-products of peroxcurrently available biomarkers of lipid peroxidation in the ide breakdown, such as malondialdehyde (MDA) and 4-human body is the isoprostanes, which are specific prodhydroxynonenal (HNE) by mass spectrometry [94, 95] .
ucts arising from the peroxidation of unsaturated fatty acid Levels of 25-140 nM MDA have been reported in human residues in lipids [19, 20, 101, [105] [106] [107] [108] [109] [110] [111] [112] [113] [114] [115] [116] [117] [118] [119] [120] . Some isoprostanes plasma [94, 96] , whereas levels of HNE vary over a wide exist free in human plasma, but most are esterified to range and have sometimes been claimed to approach 1 mM lipids. Isoprostanes can be accurately and sensitively (reviewed in [9, 95] ). These aldehydes result from breakmeasured by mass spectrometric techniques, so that down of peroxides, and thus their levels will be influenced steady-state levels in human body fluids can easily be by rates of peroxide breakdown (which are slow at 378C detected [105, 106, 119, 120] . Isoprostanes appear to turn unless transition metal ions are present [9] ), as well as by over rapidly, being both metabolised and excreted rates of metabolism of both peroxides and the aldehydes. [105, 106, 116] . Detection of them and their metabolites in There is evidence that peroxides and aldehydes in food can urine may therefore be a useful assay of 'whole-body' lipid be absorbed through the gut to a limited extent and can peroxidation [116, 120] . As a 'biomarker' of lipid peroxidapotentially confound measures of MDA (especially in tion, isoprostane analysis seems to fulfil many of the urine), TBARS, and perhaps of plasma peroxides [97- criteria listed in Table 2 . One exception is that the 101].
isoprostanes usually measured (often 8-epi-PGF ) are 2a
The discrepancy between the different levels of lipid only minor products of the peroxidation process. Several peroxidation products measured by different assays, and methodological questions relating to isoprostane analysis the question of confounding by diet, need resolution before remain to be resolved (reviewed in [105] ). The question of any of the above methods can be recommended for studies confounding by oxidized lipids in the diet has been of the effect of diet on lipid peroxidation rates in vivo. One examined experimentally, and there is no evidence as yet approach to determination of 'whole-body' lipid peroxidathat measurements of plasma isoprostanes in humans are tion has been measurement of exhaled hydrocarbons, so confounded [101, 121, 122] . especially ethane [102] [103] [104] . Hydrocarbon gases are, Most analyses of isoprostanes to date have focused on however, minor end-products of peroxidation and their measurement of some of the F -isoprostanes, which arise 2 formation, like that of aldehydes, depends on the decompofrom the peroxidation of arachidonic acid residues [106] . sition of peroxides, e.g. by transition metal ions [9] .
Levels of certain F -isoprostanes in human body fluids 2 Nevertheless, this assay has given some interesting results have been shown to be elevated in conditions that pre-(e.g. Ref. [65] ) and merits further exploration for use in dispose to accelerated development of cardiovascular intervention studies.
disease: diabetes [114, 115] , hypercholesterolaemia [107, 109] hyperhomocysteinaemia [123] and cigarette 4.2. Isoprostanes smoking [108, 110, 112] . F -isoprostane levels in humans 2 are responsive to dietary antioxidants (Table 3) , although There is a growing belief that the most valuable of the most studies have been on 'unhealthy' subjects with oxidant effects on 'healthy' volunteers need to be done; preliminary data suggest that effects are smaller. AntiRobust biomarkers of lipid peroxidation (of which at the oxidants have also been shown to decrease isoprostane moment the best available seem to be the isoprostanes) levels in animals [117, 118, [124] [125] [126] [127] . In studies on blood should be used to establish the effects of diet on lipid samples from human volunteers, plasma levels of Fperoxidation in vivo, and in particular what contribution is 2 isoprostanes showed no correlation with levels of oxidative made to any effect of diet by the antioxidants present in damage to DNA bases in white cells [128] , suggesting that that diet (ascorbate, vitamin E, carotenoids, flavonoids these two parameters are not determined by the same etc.). Any cardiovascular disease intervention trial that criteria. Indeed, whereas F -isoprostane levels appear does take place should be accompanied by measurements 2 responsive to dietary antioxidants (at least in subjects with of lipid peroxidation. This will help to assess whether any elevated F -isoprostane levels), levels of oxidative DNA beneficial effects observed on clinical end-points are 2 damage generally are not (see above). related to inhibition of lipid peroxidation, and / or to other Another potential advantage of the isoprostanes is that physiological effects [48] [49] [50] [51] [52] [60] [61] [62] [63] [64] ] of antioxidants. Meadifferent families are formed from different PUFAs surements of lipid peroxidation should be carried out: [105, [129] [130] [131] , which gives a potential mechanism for following the rates of peroxidation of different PUFAs in 1. Prior to the intervention study, to show (in short-term vivo. It is well known that increasing unsaturation enstudies) that the intervention does actually decrease hances the tendency of PUFAs to oxidize in vitro [9] , but lipid peroxidation, preferably in a dose-dependent manthe question of whether they peroxidize faster in vivo ner, in the subjects to be examined. needs to be investigated using robust assays of lipid 2. At intervals during the study, to relate changes in the peroxidation. Isoprostane 'biomarkers' arising from differlevels of lipid peroxidation to clinical end-points. ent PUFAs should be helpful in investigating the consequences of eating diets rich in various PUFAs, whether any One further point may be important. The 'steady-state' increased peroxidation that results can be ameliorated by levels of oxidative DNA damage and lipid peroxidation antioxidants (e.g. vitamin E), and if so, how much antivary widely between healthy human subjects. Are those oxidant is needed.
with high levels of lipid peroxidation more at risk of 
